Contineum Therapeutics (CTNM) Return on Invested Capital (2023 - 2024)

Contineum Therapeutics (CTNM) recorded quarterly Return on Invested Capital of 0.0% in Q3 2024, up 63.43% quarter-over-quarter from 0.01% in Q2 2024.

Contineum Therapeutics (CTNM) Return on Invested Capital (2023 - 2024) Analysis & Trends

Contineum Therapeutics' Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.0% for Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.01%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-0.01%
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-0.01%
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	0.00%
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Contineum Therapeutics	423.05 Mn	423.05 Mn	-	-

Download Data